Cancer Therapeutics signs deal with Duke University
This article was originally published in Scrip
The Australian company Cancer Therapeutics has signed an agreement with Duke University in the US to discover and develop new drugs for the treatment of different forms of cancer. The agreement will be based on the work of Duke's Professor Patrick Casey, who has been investigating lipid signalling pathways and the role of lipid metabolising enzymes in cancer and has developed a series of new inhibitors for these. Cancer Therapeutics is to begin a drug development programme to bring these early-stage compounds towards the clinic.